JP2017507915A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2017507915A5 JP2017507915A5 JP2016545920A JP2016545920A JP2017507915A5 JP 2017507915 A5 JP2017507915 A5 JP 2017507915A5 JP 2016545920 A JP2016545920 A JP 2016545920A JP 2016545920 A JP2016545920 A JP 2016545920A JP 2017507915 A5 JP2017507915 A5 JP 2017507915A5
- Authority
- JP
- Japan
- Prior art keywords
- methyl
- furan
- hydroxyformamido
- heptanamido
- carbamoyl
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Ceased
Links
- -1 —CO 2 H Chemical group 0.000 claims 63
- 125000002496 methyl group Chemical group [H]C([H])([H])* 0.000 claims 59
- 125000004178 (C1-C4) alkyl group Chemical group 0.000 claims 26
- 150000001875 compounds Chemical class 0.000 claims 23
- AEDIXYWIVPYNBI-UHFFFAOYSA-N heptanamide Chemical compound CCCCCCC(N)=O AEDIXYWIVPYNBI-UHFFFAOYSA-N 0.000 claims 19
- 150000003839 salts Chemical class 0.000 claims 19
- KDGKTJGPFXIBEB-UHFFFAOYSA-N n-hydroxyformamide Chemical compound ONC=O KDGKTJGPFXIBEB-UHFFFAOYSA-N 0.000 claims 18
- 239000002253 acid Substances 0.000 claims 16
- 125000002887 hydroxy group Chemical group [H]O* 0.000 claims 15
- TVFIYRKPCACCNL-UHFFFAOYSA-N furan-2-carboxamide Chemical compound NC(=O)C1=CC=CO1 TVFIYRKPCACCNL-UHFFFAOYSA-N 0.000 claims 14
- 125000003917 carbamoyl group Chemical group [H]N([H])C(*)=O 0.000 claims 13
- 125000002941 2-furyl group Chemical group O1C([*])=C([H])C([H])=C1[H] 0.000 claims 12
- 125000006526 (C1-C2) alkyl group Chemical group 0.000 claims 10
- 125000001997 phenyl group Chemical group [H]C1=C([H])C([H])=C(*)C([H])=C1[H] 0.000 claims 10
- ICJNEJGCTNSQEN-UYAOXDASSA-N CCCCC[C@H]([C@@H](CC)N(C=O)O)C(NCNC(C1=C(C2=CC(C(O)=O)=CC=C2)OC=C1)=O)=O Chemical compound CCCCC[C@H]([C@@H](CC)N(C=O)O)C(NCNC(C1=C(C2=CC(C(O)=O)=CC=C2)OC=C1)=O)=O ICJNEJGCTNSQEN-UYAOXDASSA-N 0.000 claims 9
- 125000000217 alkyl group Chemical group 0.000 claims 8
- 125000005843 halogen group Chemical group 0.000 claims 8
- ABLZXFCXXLZCGV-UHFFFAOYSA-N Phosphorous acid Chemical compound OP(O)=O ABLZXFCXXLZCGV-UHFFFAOYSA-N 0.000 claims 5
- 125000004093 cyano group Chemical group *C#N 0.000 claims 5
- 201000010099 disease Diseases 0.000 claims 5
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 claims 5
- 239000000203 mixture Substances 0.000 claims 5
- 125000000229 (C1-C4)alkoxy group Chemical group 0.000 claims 4
- IJGRMHOSHXDMSA-UHFFFAOYSA-N Atomic nitrogen Chemical compound N#N IJGRMHOSHXDMSA-UHFFFAOYSA-N 0.000 claims 4
- KXDAEFPNCMNJSK-UHFFFAOYSA-N benzene carboxamide Natural products NC(=O)C1=CC=CC=C1 KXDAEFPNCMNJSK-UHFFFAOYSA-N 0.000 claims 4
- 125000000623 heterocyclic group Chemical group 0.000 claims 4
- 125000001424 substituent group Chemical group 0.000 claims 4
- KDYFGRWQOYBRFD-UHFFFAOYSA-N succinic acid Chemical compound OC(=O)CCC(O)=O KDYFGRWQOYBRFD-UHFFFAOYSA-N 0.000 claims 4
- 102000004152 Bone morphogenetic protein 1 Human genes 0.000 claims 3
- 108090000654 Bone morphogenetic protein 1 Proteins 0.000 claims 3
- 101000637851 Homo sapiens Tolloid-like protein 1 Proteins 0.000 claims 3
- 101000637850 Homo sapiens Tolloid-like protein 2 Proteins 0.000 claims 3
- 102100031996 Tolloid-like protein 1 Human genes 0.000 claims 3
- 102100031997 Tolloid-like protein 2 Human genes 0.000 claims 3
- 230000000694 effects Effects 0.000 claims 3
- 125000001153 fluoro group Chemical group F* 0.000 claims 3
- 230000037390 scarring Effects 0.000 claims 3
- 125000006273 (C1-C3) alkyl group Chemical group 0.000 claims 2
- 125000004169 (C1-C6) alkyl group Chemical group 0.000 claims 2
- 125000005913 (C3-C6) cycloalkyl group Chemical group 0.000 claims 2
- JNIYNIYDWZGBOX-UHFFFAOYSA-N 2-[5-[[2-[[formyl(hydroxy)amino]methyl]heptanoylamino]methylcarbamoyl]furan-2-yl]benzoic acid Chemical compound ON(C=O)CC(C(=O)NCNC(=O)C1=CC=C(O1)C1=C(C(=O)O)C=CC=C1)CCCCC JNIYNIYDWZGBOX-UHFFFAOYSA-N 0.000 claims 2
- 208000006545 Chronic Obstructive Pulmonary Disease Diseases 0.000 claims 2
- 201000009794 Idiopathic Pulmonary Fibrosis Diseases 0.000 claims 2
- LOMBIJYMBPCNPY-YLJYHZDGSA-N ON(C=O)[C@H](CC)[C@H](C(=O)NCNC(=O)C1=C(OC=C1)C1=CC=C(C(C(=O)O)=C1)C(=O)O)CCCCC Chemical compound ON(C=O)[C@H](CC)[C@H](C(=O)NCNC(=O)C1=C(OC=C1)C1=CC=C(C(C(=O)O)=C1)C(=O)O)CCCCC LOMBIJYMBPCNPY-YLJYHZDGSA-N 0.000 claims 2
- 125000003545 alkoxy group Chemical group 0.000 claims 2
- QVGXLLKOCUKJST-UHFFFAOYSA-N atomic oxygen Chemical compound [O] QVGXLLKOCUKJST-UHFFFAOYSA-N 0.000 claims 2
- 125000000043 benzamido group Chemical group [H]N([*])C(=O)C1=C([H])C([H])=C([H])C([H])=C1[H] 0.000 claims 2
- 208000020832 chronic kidney disease Diseases 0.000 claims 2
- 125000000000 cycloalkoxy group Chemical group 0.000 claims 2
- 125000000753 cycloalkyl group Chemical group 0.000 claims 2
- 125000001559 cyclopropyl group Chemical group [H]C1([H])C([H])([H])C1([H])* 0.000 claims 2
- JFCQEDHGNNZCLN-UHFFFAOYSA-N glutaric acid Chemical compound OC(=O)CCCC(O)=O JFCQEDHGNNZCLN-UHFFFAOYSA-N 0.000 claims 2
- 125000001072 heteroaryl group Chemical group 0.000 claims 2
- 201000006938 muscular dystrophy Diseases 0.000 claims 2
- 125000000449 nitro group Chemical group [O-][N+](*)=O 0.000 claims 2
- 229910052757 nitrogen Inorganic materials 0.000 claims 2
- 206010053219 non-alcoholic steatohepatitis Diseases 0.000 claims 2
- 125000004043 oxo group Chemical group O=* 0.000 claims 2
- 229910052760 oxygen Inorganic materials 0.000 claims 2
- 239000001301 oxygen Substances 0.000 claims 2
- 125000006413 ring segment Chemical group 0.000 claims 2
- 239000001384 succinic acid Substances 0.000 claims 2
- 125000004213 tert-butoxy group Chemical group [H]C([H])([H])C(O*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 2
- RWRDLPDLKQPQOW-UHFFFAOYSA-N tetrahydropyrrole Natural products C1CCNC1 RWRDLPDLKQPQOW-UHFFFAOYSA-N 0.000 claims 2
- RBBYBZRCJCSVLZ-XPWALMASSA-N (2S)-2-[[2-[2-ethoxy-4-[5-[[[(2R)-2-[(1R)-1-[formyl(hydroxy)amino]propyl]heptanoyl]amino]methylcarbamoyl]furan-2-yl]phenyl]acetyl]amino]butanedioic acid Chemical compound CCCCC[C@H]([C@@H](CC)N(O)C=O)C(=O)NCNC(=O)C1=CC=C(O1)C1=CC(OCC)=C(CC(=O)N[C@@H](CC(O)=O)C(O)=O)C=C1 RBBYBZRCJCSVLZ-XPWALMASSA-N 0.000 claims 1
- OOYCZSDPTUAUHM-IEZKXTBUSA-N (2S)-2-[[4-[5-[[[(2R,3R)-2-[2-(2,4-difluorophenyl)ethyl]-3-[formyl(hydroxy)amino]pentanoyl]amino]methylcarbamoyl]furan-2-yl]-2-ethoxybenzoyl]amino]butanedioic acid Chemical compound FC1=C(C=CC(=C1)F)CC[C@@H](C(=O)NCNC(=O)C1=CC=C(O1)C1=CC(=C(C(=O)N[C@H](C(=O)O)CC(=O)O)C=C1)OCC)[C@@H](CC)N(C=O)O OOYCZSDPTUAUHM-IEZKXTBUSA-N 0.000 claims 1
- 125000004191 (C1-C6) alkoxy group Chemical group 0.000 claims 1
- AZCVVKKSIGSIBN-NHCUHLMSSA-N 1-[4-[5-[[[(2R)-2-[(1R)-1-[formyl(hydroxy)amino]propyl]heptanoyl]amino]methylcarbamoyl]furan-2-yl]phenyl]cyclopropane-1-carboxylic acid Chemical compound ON(C=O)[C@H](CC)[C@H](C(=O)NCNC(=O)C1=CC=C(O1)C1=CC=C(C=C1)C1(CC1)C(=O)O)CCCCC AZCVVKKSIGSIBN-NHCUHLMSSA-N 0.000 claims 1
- OJDWWBUOFLCESN-CYBMUJFWSA-N 2,6-difluoro-3-[5-[[[(2R)-2-[[formyl(hydroxy)amino]methyl]heptanoyl]amino]methylcarbamoyl]furan-2-yl]benzoic acid Chemical compound FC1=C(C(=O)O)C(=CC=C1C=1OC(=CC=1)C(NCNC([C@H](CCCCC)CN(C=O)O)=O)=O)F OJDWWBUOFLCESN-CYBMUJFWSA-N 0.000 claims 1
- UWJMRCZZRINSHA-NHCUHLMSSA-N 2-[3-[5-[[[(2R)-2-[(1R)-1-[formyl(hydroxy)amino]propyl]heptanoyl]amino]methylcarbamoyl]furan-2-yl]phenyl]-2-methylpropanoic acid Chemical compound ON(C=O)[C@H](CC)[C@H](C(=O)NCNC(=O)C1=CC=C(O1)C=1C=C(C=CC1)C(C(=O)O)(C)C)CCCCC UWJMRCZZRINSHA-NHCUHLMSSA-N 0.000 claims 1
- NKGCXRHPXKPRGE-GOSISDBHSA-N 2-[3-[5-[[[(2R)-2-[[formyl(hydroxy)amino]methyl]heptanoyl]amino]methylcarbamoyl]furan-2-yl]phenyl]acetic acid Chemical compound ON(C=O)C[C@H](C(=O)NCNC(=O)C1=CC=C(O1)C=1C=C(C=CC=1)CC(=O)O)CCCCC NKGCXRHPXKPRGE-GOSISDBHSA-N 0.000 claims 1
- OJYJMDRAFRSACC-LRTDYKAYSA-N 2-[3-[5-[[[(2R)-2-[[formyl(hydroxy)amino]methyl]heptanoyl]amino]methylcarbamoyl]furan-2-yl]phenyl]propanoic acid Chemical compound ON(C=O)C[C@H](C(=O)NCNC(=O)C1=CC=C(O1)C=1C=C(C=CC1)C(C(=O)O)C)CCCCC OJYJMDRAFRSACC-LRTDYKAYSA-N 0.000 claims 1
- KLWCQQLVUFBCSJ-NHCUHLMSSA-N 2-[3-ethoxy-5-[5-[[[(2R)-2-[(1R)-1-[formyl(hydroxy)amino]propyl]heptanoyl]amino]methylcarbamoyl]furan-2-yl]phenyl]-2,2-difluoroacetic acid Chemical compound C(C)OC=1C=C(C=C(C1)C=1OC(=CC1)C(NCNC([C@H](CCCCC)[C@@H](CC)N(C=O)O)=O)=O)C(C(=O)O)(F)F KLWCQQLVUFBCSJ-NHCUHLMSSA-N 0.000 claims 1
- CSOOXMLPHMLROL-NHCUHLMSSA-N 2-[4-[5-[[[(2R)-2-[(1R)-1-[formyl(hydroxy)amino]propyl]heptanoyl]amino]methylcarbamoyl]furan-2-yl]phenyl]-2-methylpropanoic acid Chemical compound ON(C=O)[C@H](CC)[C@H](C(=O)NCNC(=O)C1=CC=C(O1)C1=CC=C(C=C1)C(C(=O)O)(C)C)CCCCC CSOOXMLPHMLROL-NHCUHLMSSA-N 0.000 claims 1
- OOQSODFEUOWYPX-WOJBJXKFSA-N 2-[4-[5-[[[(2R)-2-[(1R)-1-[formyl(hydroxy)amino]propyl]heptanoyl]amino]methylcarbamoyl]furan-2-yl]phenyl]acetic acid Chemical compound ON(C=O)[C@H](CC)[C@H](C(=O)NCNC(=O)C1=CC=C(O1)C1=CC=C(C=C1)CC(=O)O)CCCCC OOQSODFEUOWYPX-WOJBJXKFSA-N 0.000 claims 1
- JNIYNIYDWZGBOX-OAHLLOKOSA-N 2-[5-[[[(2R)-2-[[formyl(hydroxy)amino]methyl]heptanoyl]amino]methylcarbamoyl]furan-2-yl]benzoic acid Chemical compound ON(C=O)C[C@H](C(=O)NCNC(=O)C1=CC=C(O1)C1=C(C(=O)O)C=CC=C1)CCCCC JNIYNIYDWZGBOX-OAHLLOKOSA-N 0.000 claims 1
- VOIDFWWWMVOASZ-DNQXCXABSA-N 2-[[3-ethoxy-5-[5-[[[(2R)-2-[(1R)-1-[formyl(hydroxy)amino]propyl]heptanoyl]amino]methylcarbamoyl]furan-2-yl]phenyl]methyl-methylamino]acetic acid Chemical compound C(C)OC=1C=C(CN(CC(=O)O)C)C=C(C1)C=1OC(=CC1)C(NCNC([C@H](CCCCC)[C@@H](CC)N(C=O)O)=O)=O VOIDFWWWMVOASZ-DNQXCXABSA-N 0.000 claims 1
- XUYXGZGYBSPCEY-ILBGXUMGSA-N 2-[carboxymethyl-[2-ethoxy-4-[5-[[[(2R,3R)-3-[formyl(hydroxy)amino]-2-(2-phenylethyl)pentanoyl]amino]methylcarbamoyl]furan-2-yl]benzoyl]amino]acetic acid Chemical compound C(C)OC1=C(C(=O)N(CC(=O)O)CC(=O)O)C=CC(=C1)C=1OC(=CC1)C(NCNC([C@@H]([C@@H](CC)N(C=O)O)CCC1=CC=CC=C1)=O)=O XUYXGZGYBSPCEY-ILBGXUMGSA-N 0.000 claims 1
- GKBOXHJWFVZMHR-AOYPEHQESA-N 2-[carboxymethyl-[3-[5-[[[(2R,3R)-2-[2-(2,4-difluorophenyl)ethyl]-3-[formyl(hydroxy)amino]pentanoyl]amino]methylcarbamoyl]furan-2-yl]-5-ethoxybenzoyl]amino]acetic acid Chemical compound FC1=C(CC[C@@H](C(=O)NCNC(=O)C2=CC=C(O2)C=2C=C(C(=O)N(CC(=O)O)CC(=O)O)C=C(C=2)OCC)[C@@H](CC)N(C=O)O)C=CC(=C1)F GKBOXHJWFVZMHR-AOYPEHQESA-N 0.000 claims 1
- YEDIUVJCFVQHFT-DHIUTWEWSA-N 2-[carboxymethyl-[3-ethoxy-5-[5-[[[(2R)-2-[(1R)-1-[formyl(hydroxy)amino]propyl]heptanoyl]amino]methylcarbamoyl]furan-2-yl]benzoyl]amino]acetic acid Chemical compound C(C)OC=1C=C(C(=O)N(CC(=O)O)CC(=O)O)C=C(C1)C=1OC(=CC1)C(NCNC([C@H](CCCCC)[C@@H](CC)N(C=O)O)=O)=O YEDIUVJCFVQHFT-DHIUTWEWSA-N 0.000 claims 1
- FEGGHDNFYOHIAS-OAHLLOKOSA-N 2-amino-5-[5-[[[(2R)-2-[[formyl(hydroxy)amino]methyl]heptanoyl]amino]methylcarbamoyl]furan-2-yl]benzoic acid Chemical compound NC1=C(C(=O)O)C=C(C=C1)C=1OC(=CC1)C(NCNC([C@H](CCCCC)CN(C=O)O)=O)=O FEGGHDNFYOHIAS-OAHLLOKOSA-N 0.000 claims 1
- 125000006176 2-ethylbutyl group Chemical group [H]C([H])([H])C([H])([H])C([H])(C([H])([H])*)C([H])([H])C([H])([H])[H] 0.000 claims 1
- JAYZKDJRODJAHD-CQSZACIVSA-N 2-fluoro-3-[5-[[[(2R)-2-[[formyl(hydroxy)amino]methyl]heptanoyl]amino]methylcarbamoyl]furan-2-yl]benzoic acid Chemical compound FC1=C(C(=O)O)C=CC=C1C=1OC(=CC=1)C(NCNC([C@H](CCCCC)CN(C=O)O)=O)=O JAYZKDJRODJAHD-CQSZACIVSA-N 0.000 claims 1
- VFQLAARGYVURHL-UHFFFAOYSA-N 2-fluoro-5-[5-[[2-[[formyl(hydroxy)amino]methyl]heptanoylamino]methylcarbamoyl]furan-2-yl]benzoic acid Chemical compound CCCCCC(CN(O)C=O)C(=O)NCNC(=O)c1ccc(o1)-c1ccc(F)c(c1)C(O)=O VFQLAARGYVURHL-UHFFFAOYSA-N 0.000 claims 1
- VFQLAARGYVURHL-OAHLLOKOSA-N 2-fluoro-5-[5-[[[(2R)-2-[[formyl(hydroxy)amino]methyl]heptanoyl]amino]methylcarbamoyl]furan-2-yl]benzoic acid Chemical compound FC1=C(C(=O)O)C=C(C=C1)C=1OC(=CC=1)C(NCNC([C@H](CCCCC)CN(C=O)O)=O)=O VFQLAARGYVURHL-OAHLLOKOSA-N 0.000 claims 1
- 125000004924 2-naphthylethyl group Chemical group C1=C(C=CC2=CC=CC=C12)CC* 0.000 claims 1
- 125000000094 2-phenylethyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])* 0.000 claims 1
- CIYVDOLHZQTJRJ-WOJBJXKFSA-N 3-(2-amino-2-oxoethoxy)-5-[5-[[[(2R)-2-[(1R)-1-[formyl(hydroxy)amino]propyl]heptanoyl]amino]methylcarbamoyl]furan-2-yl]benzoic acid Chemical compound NC(COC=1C=C(C(=O)O)C=C(C=1)C=1OC(=CC=1)C(NCNC([C@H](CCCCC)[C@@H](CC)N(C=O)O)=O)=O)=O CIYVDOLHZQTJRJ-WOJBJXKFSA-N 0.000 claims 1
- OLVGYZQTVBDCLJ-WOJBJXKFSA-N 3-(carboxymethoxy)-5-[5-[[[(2R)-2-[(1R)-1-[formyl(hydroxy)amino]propyl]heptanoyl]amino]methylcarbamoyl]furan-2-yl]benzoic acid Chemical compound C(=O)(O)COC=1C=C(C(=O)O)C=C(C=1)C=1OC(=CC=1)C(NCNC([C@H](CCCCC)[C@@H](CC)N(C=O)O)=O)=O OLVGYZQTVBDCLJ-WOJBJXKFSA-N 0.000 claims 1
- SDTSNZJWXCVNMT-UHFFFAOYSA-N 3-[5-[[2-[[formyl(hydroxy)amino]methyl]heptanoylamino]methylcarbamoyl]furan-2-yl]benzoic acid Chemical compound CCCCCC(CN(O)C=O)C(=O)NCNC(=O)c1ccc(o1)-c1cccc(c1)C(O)=O SDTSNZJWXCVNMT-UHFFFAOYSA-N 0.000 claims 1
- CCQZNGVTACLZPG-FGZHOGPDSA-N 3-[5-[[[(2R)-2-[(1R)-1-[formyl(hydroxy)amino]propyl]heptanoyl]amino]methylcarbamoyl]furan-2-yl]-5-propoxybenzoic acid Chemical compound ON(C=O)[C@H](CC)[C@H](C(=O)NCNC(=O)C1=CC=C(O1)C=1C=C(C(=O)O)C=C(C1)OCCC)CCCCC CCQZNGVTACLZPG-FGZHOGPDSA-N 0.000 claims 1
- SDZJEFRAJDSNQW-OAHLLOKOSA-N 3-[5-[[[(2R)-2-[[formyl(hydroxy)amino]methyl]heptanoyl]amino]methylcarbamoyl]furan-2-yl]-2-methoxybenzoic acid Chemical compound ON(C=O)C[C@H](C(=O)NCNC(=O)C1=CC=C(O1)C=1C(=C(C(=O)O)C=CC1)OC)CCCCC SDZJEFRAJDSNQW-OAHLLOKOSA-N 0.000 claims 1
- KPVFOUNLQKBYIP-MRXNPFEDSA-N 3-[5-[[[(2R)-2-[[formyl(hydroxy)amino]methyl]heptanoyl]amino]methylcarbamoyl]furan-2-yl]-2-methylbenzoic acid Chemical compound ON(C=O)C[C@H](C(=O)NCNC(=O)C1=CC=C(O1)C=1C(=C(C(=O)O)C=CC1)C)CCCCC KPVFOUNLQKBYIP-MRXNPFEDSA-N 0.000 claims 1
- NZZQNOHKPCQKKC-IEBWSBKVSA-N 3-ethoxy-2-fluoro-5-[5-[[[(2R)-2-[(1R)-1-[formyl(hydroxy)amino]propyl]heptanoyl]amino]methylcarbamoyl]furan-2-yl]benzoic acid Chemical compound C(C)OC=1C(=C(C(=O)O)C=C(C=1)C=1OC(=CC=1)C(NCNC([C@H](CCCCC)[C@@H](CC)N(C=O)O)=O)=O)F NZZQNOHKPCQKKC-IEBWSBKVSA-N 0.000 claims 1
- BRHPGJGDRPZCNS-MRXNPFEDSA-N 3-ethoxy-5-[5-[[[(2R)-2-[[formyl(hydroxy)amino]methyl]heptanoyl]amino]methylcarbamoyl]furan-2-yl]benzoic acid Chemical compound C(C)OC=1C=C(C(=O)O)C=C(C=1)C=1OC(=CC=1)C(NCNC([C@H](CCCCC)CN(C=O)O)=O)=O BRHPGJGDRPZCNS-MRXNPFEDSA-N 0.000 claims 1
- 125000006201 3-phenylpropyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- OBUCNGYFEHMNAD-QGZVFWFLSA-N 4-[5-[[[(2R)-2-[[formyl(hydroxy)amino]methyl]heptanoyl]amino]methylcarbamoyl]furan-2-yl]benzoic acid Chemical compound ON(C=O)C[C@H](C(=O)NCNC(=O)C1=CC=C(O1)C1=CC=C(C(=O)O)C=C1)CCCCC OBUCNGYFEHMNAD-QGZVFWFLSA-N 0.000 claims 1
- 125000004801 4-cyanophenyl group Chemical group [H]C1=C([H])C(C#N)=C([H])C([H])=C1* 0.000 claims 1
- MVGYSELXXWZWIN-VQIMIIECSA-N 5-(carboxymethoxy)-3-[5-[[[(2R)-2-[(1R)-1-[formyl(hydroxy)amino]propyl]heptanoyl]amino]methylcarbamoyl]furan-2-yl]-2-hydroxybenzoic acid Chemical compound C(=O)(O)COC=1C=C(C(=C(C(=O)O)C1)O)C=1OC(=CC1)C(NCNC([C@H](CCCCC)[C@@H](CC)N(C=O)O)=O)=O MVGYSELXXWZWIN-VQIMIIECSA-N 0.000 claims 1
- CYPUWXZJVPSHHD-IEBWSBKVSA-N 5-[5-[[[(2R)-2-[(1R)-1-[formyl(hydroxy)amino]propyl]heptanoyl]amino]methylcarbamoyl]furan-2-yl]-2-methoxybenzoic acid Chemical compound ON(C=O)[C@H](CC)[C@H](C(=O)NCNC(=O)C1=CC=C(O1)C=1C=CC(=C(C(=O)O)C1)OC)CCCCC CYPUWXZJVPSHHD-IEBWSBKVSA-N 0.000 claims 1
- HOSZYAKZPYGGQV-UYAOXDASSA-N 5-[5-[[[(2R)-2-[(1R)-1-[formyl(hydroxy)amino]propyl]heptanoyl]amino]methylcarbamoyl]furan-2-yl]-2-methylbenzoic acid Chemical compound ON(C=O)[C@H](CC)[C@H](C(=O)NCNC(=O)C1=CC=C(O1)C=1C=CC(=C(C(=O)O)C1)C)CCCCC HOSZYAKZPYGGQV-UYAOXDASSA-N 0.000 claims 1
- KVJPULCOPXGRLR-QZTJIDSGSA-N 5-[5-[[[(2R)-2-[(1R)-1-[formyl(hydroxy)amino]propyl]heptanoyl]amino]methylcarbamoyl]furan-2-yl]pyridine-3-carboxylic acid Chemical compound ON(C=O)[C@H](CC)[C@H](C(=O)NCNC(=O)C1=CC=C(O1)C=1C=NC=C(C(=O)O)C1)CCCCC KVJPULCOPXGRLR-QZTJIDSGSA-N 0.000 claims 1
- KQFXPMDLKBVKFX-OAHLLOKOSA-N 5-[5-[[[(2R)-2-[[formyl(hydroxy)amino]methyl]heptanoyl]amino]methylcarbamoyl]furan-2-yl]-2-hydroxybenzoic acid Chemical compound OC1=C(C(=O)O)C=C(C=C1)C=1OC(=CC=1)C(NCNC([C@H](CCCCC)CN(C=O)O)=O)=O KQFXPMDLKBVKFX-OAHLLOKOSA-N 0.000 claims 1
- 208000009304 Acute Kidney Injury Diseases 0.000 claims 1
- 206010006895 Cachexia Diseases 0.000 claims 1
- 208000029147 Collagen-vascular disease Diseases 0.000 claims 1
- 208000007342 Diabetic Nephropathies Diseases 0.000 claims 1
- 206010016654 Fibrosis Diseases 0.000 claims 1
- 208000010412 Glaucoma Diseases 0.000 claims 1
- 206010019280 Heart failures Diseases 0.000 claims 1
- 208000002260 Keloid Diseases 0.000 claims 1
- 206010023330 Keloid scar Diseases 0.000 claims 1
- 208000029578 Muscle disease Diseases 0.000 claims 1
- 208000021642 Muscular disease Diseases 0.000 claims 1
- VQWFQBPLTXSGQV-GOSISDBHSA-N N-[[[(2R)-2-(cyclopentylmethyl)-3-[formyl(hydroxy)amino]propanoyl]amino]methyl]-5-phenylfuran-2-carboxamide Chemical compound C1(CCCC1)C[C@@H](C(=O)NCNC(=O)C=1OC(=CC1)C1=CC=CC=C1)CN(C=O)O VQWFQBPLTXSGQV-GOSISDBHSA-N 0.000 claims 1
- BTZOUHZSWKLMGS-OAQYLSRUSA-N N-[[[(2R)-2-[[formyl(hydroxy)amino]methyl]-5-phenylpentanoyl]amino]methyl]-5-phenylfuran-2-carboxamide Chemical compound ON(C=O)C[C@H](C(=O)NCNC(=O)C=1OC(=CC1)C1=CC=CC=C1)CCCC1=CC=CC=C1 BTZOUHZSWKLMGS-OAQYLSRUSA-N 0.000 claims 1
- MBBZMMPHUWSWHV-BDVNFPICSA-N N-methylglucamine Chemical compound CNC[C@H](O)[C@@H](O)[C@H](O)[C@H](O)CO MBBZMMPHUWSWHV-BDVNFPICSA-N 0.000 claims 1
- RUIPSIFDZGPPRO-GZJHNZOKSA-N ON(C=O)[C@H](CC)[C@H](C(=O)NCNC(=O)C1=CC=C(O1)C=1C=C(OCC(=O)O)C=C(C1)P(=O)(O)O)CCCCC.P(O)(O)=O Chemical compound ON(C=O)[C@H](CC)[C@H](C(=O)NCNC(=O)C1=CC=C(O1)C=1C=C(OCC(=O)O)C=C(C1)P(=O)(O)O)CCCCC.P(O)(O)=O RUIPSIFDZGPPRO-GZJHNZOKSA-N 0.000 claims 1
- 208000033626 Renal failure acute Diseases 0.000 claims 1
- 206010039710 Scleroderma Diseases 0.000 claims 1
- 208000006011 Stroke Diseases 0.000 claims 1
- NINIDFKCEFEMDL-UHFFFAOYSA-N Sulfur Chemical compound [S] NINIDFKCEFEMDL-UHFFFAOYSA-N 0.000 claims 1
- 239000007983 Tris buffer Substances 0.000 claims 1
- FKPYKQOAWVRRMM-QGZVFWFLSA-N [3-[5-[[[(2R)-2-[[formyl(hydroxy)amino]methyl]heptanoyl]amino]methylcarbamoyl]furan-2-yl]phenyl]-methylphosphinic acid Chemical compound ON(C=O)C[C@H](C(=O)NCNC(=O)C1=CC=C(O1)C=1C=C(C=CC1)P(O)(=O)C)CCCCC FKPYKQOAWVRRMM-QGZVFWFLSA-N 0.000 claims 1
- WKSRBBBAXCUOST-VSGBNLITSA-N [3-ethoxy-5-[5-[[[(2R,3R)-3-[formyl(hydroxy)amino]-2-(2-naphthalen-2-ylethyl)pentanoyl]amino]methylcarbamoyl]furan-2-yl]phenyl]phosphonic acid Chemical compound C(C)OC=1C=C(C=C(C=1)C=1OC(=CC=1)C(NCNC([C@@H]([C@@H](CC)N(C=O)O)CCC1=CC2=CC=CC=C2C=C1)=O)=O)P(O)(O)=O WKSRBBBAXCUOST-VSGBNLITSA-N 0.000 claims 1
- 150000007513 acids Chemical class 0.000 claims 1
- 201000011040 acute kidney failure Diseases 0.000 claims 1
- 125000005037 alkyl phenyl group Chemical group 0.000 claims 1
- 206010003119 arrhythmia Diseases 0.000 claims 1
- 125000001797 benzyl group Chemical group [H]C1=C([H])C([H])=C(C([H])=C1[H])C([H])([H])* 0.000 claims 1
- 159000000007 calcium salts Chemical class 0.000 claims 1
- 125000002057 carboxymethyl group Chemical group [H]OC(=O)C([H])([H])[*] 0.000 claims 1
- 230000007882 cirrhosis Effects 0.000 claims 1
- 208000019425 cirrhosis of liver Diseases 0.000 claims 1
- YMGUBTXCNDTFJI-UHFFFAOYSA-N cyclopropanecarboxylic acid Chemical compound OC(=O)C1CC1 YMGUBTXCNDTFJI-UHFFFAOYSA-N 0.000 claims 1
- 208000033679 diabetic kidney disease Diseases 0.000 claims 1
- 125000000118 dimethyl group Chemical group [H]C([H])([H])* 0.000 claims 1
- 125000001301 ethoxy group Chemical group [H]C([H])([H])C([H])([H])O* 0.000 claims 1
- 125000001495 ethyl group Chemical group [H]C([H])([H])C([H])([H])* 0.000 claims 1
- 210000001508 eye Anatomy 0.000 claims 1
- 230000003176 fibrotic effect Effects 0.000 claims 1
- 210000002216 heart Anatomy 0.000 claims 1
- 239000001257 hydrogen Substances 0.000 claims 1
- 229910052739 hydrogen Inorganic materials 0.000 claims 1
- 206010020871 hypertrophic cardiomyopathy Diseases 0.000 claims 1
- 230000001969 hypertrophic effect Effects 0.000 claims 1
- 125000003453 indazolyl group Chemical group N1N=C(C2=C1C=CC=C2)* 0.000 claims 1
- 208000014674 injury Diseases 0.000 claims 1
- 208000036971 interstitial lung disease 2 Diseases 0.000 claims 1
- 125000001786 isothiazolyl group Chemical group 0.000 claims 1
- 210000001117 keloid Anatomy 0.000 claims 1
- 210000003734 kidney Anatomy 0.000 claims 1
- 230000003907 kidney function Effects 0.000 claims 1
- 210000004185 liver Anatomy 0.000 claims 1
- 210000004072 lung Anatomy 0.000 claims 1
- 229960003194 meglumine Drugs 0.000 claims 1
- 125000002950 monocyclic group Chemical group 0.000 claims 1
- 201000006417 multiple sclerosis Diseases 0.000 claims 1
- 230000004220 muscle function Effects 0.000 claims 1
- 208000010125 myocardial infarction Diseases 0.000 claims 1
- 125000000740 n-pentyl group Chemical group [H]C([H])([H])C([H])([H])C([H])([H])C([H])([H])C([H])([H])* 0.000 claims 1
- 125000001624 naphthyl group Chemical group 0.000 claims 1
- 210000000653 nervous system Anatomy 0.000 claims 1
- 208000008338 non-alcoholic fatty liver disease Diseases 0.000 claims 1
- 125000002971 oxazolyl group Chemical group 0.000 claims 1
- 230000001575 pathological effect Effects 0.000 claims 1
- 239000008194 pharmaceutical composition Substances 0.000 claims 1
- 239000000546 pharmaceutical excipient Substances 0.000 claims 1
- 125000002924 primary amino group Chemical group [H]N([H])* 0.000 claims 1
- 125000001436 propyl group Chemical group [H]C([*])([H])C([H])([H])C([H])([H])[H] 0.000 claims 1
- 125000003226 pyrazolyl group Chemical group 0.000 claims 1
- 125000002098 pyridazinyl group Chemical group 0.000 claims 1
- 125000004076 pyridyl group Chemical group 0.000 claims 1
- 125000000714 pyrimidinyl group Chemical group 0.000 claims 1
- 125000000719 pyrrolidinyl group Chemical group 0.000 claims 1
- 206010039073 rheumatoid arthritis Diseases 0.000 claims 1
- 208000001076 sarcopenia Diseases 0.000 claims 1
- 210000002027 skeletal muscle Anatomy 0.000 claims 1
- 210000003491 skin Anatomy 0.000 claims 1
- 208000020431 spinal cord injury Diseases 0.000 claims 1
- 239000011593 sulfur Substances 0.000 claims 1
- 229910052717 sulfur Inorganic materials 0.000 claims 1
- 238000001356 surgical procedure Methods 0.000 claims 1
- 201000000596 systemic lupus erythematosus Diseases 0.000 claims 1
- 125000000999 tert-butyl group Chemical group [H]C([H])([H])C(*)(C([H])([H])[H])C([H])([H])[H] 0.000 claims 1
- 125000003831 tetrazolyl group Chemical group 0.000 claims 1
- 238000002054 transplantation Methods 0.000 claims 1
- 230000008733 trauma Effects 0.000 claims 1
- 210000005166 vasculature Anatomy 0.000 claims 1
- 230000029663 wound healing Effects 0.000 claims 1
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201461925848P | 2014-01-10 | 2014-01-10 | |
| US61/925,848 | 2014-01-10 | ||
| PCT/IB2015/050179 WO2015104684A1 (en) | 2014-01-10 | 2015-01-09 | Hydroxy formamide derivatives and their use |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019160658A Division JP2020011968A (ja) | 2014-01-10 | 2019-09-03 | ヒドロキシホルムアミド誘導体およびそれらの使用 |
Publications (2)
| Publication Number | Publication Date |
|---|---|
| JP2017507915A JP2017507915A (ja) | 2017-03-23 |
| JP2017507915A5 true JP2017507915A5 (OSRAM) | 2018-02-22 |
Family
ID=52440747
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2016545920A Ceased JP2017507915A (ja) | 2014-01-10 | 2015-01-09 | ヒドロキシホルムアミド誘導体およびそれらの使用 |
| JP2019160658A Pending JP2020011968A (ja) | 2014-01-10 | 2019-09-03 | ヒドロキシホルムアミド誘導体およびそれらの使用 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2019160658A Pending JP2020011968A (ja) | 2014-01-10 | 2019-09-03 | ヒドロキシホルムアミド誘導体およびそれらの使用 |
Country Status (21)
| Country | Link |
|---|---|
| US (2) | US10450288B2 (OSRAM) |
| EP (1) | EP3092233A1 (OSRAM) |
| JP (2) | JP2017507915A (OSRAM) |
| KR (1) | KR20160106684A (OSRAM) |
| CN (2) | CN106103431B (OSRAM) |
| AU (1) | AU2015205370B2 (OSRAM) |
| BR (1) | BR112016016130A2 (OSRAM) |
| CA (1) | CA2936467A1 (OSRAM) |
| CL (1) | CL2016001746A1 (OSRAM) |
| CR (1) | CR20160316A (OSRAM) |
| DO (1) | DOP2016000170A (OSRAM) |
| EA (1) | EA031654B1 (OSRAM) |
| IL (1) | IL246653A0 (OSRAM) |
| MA (1) | MA39171A1 (OSRAM) |
| MX (1) | MX2016009064A (OSRAM) |
| PE (1) | PE20160998A1 (OSRAM) |
| PH (1) | PH12016501349A1 (OSRAM) |
| SG (1) | SG11201605539SA (OSRAM) |
| TW (1) | TW201620887A (OSRAM) |
| UA (1) | UA118278C2 (OSRAM) |
| WO (1) | WO2015104684A1 (OSRAM) |
Families Citing this family (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| PE20160998A1 (es) * | 2014-01-10 | 2016-10-26 | Glaxosmithkline Intellectual Property (No 2) Ltd | Derivados de n-((3-(n-hidroxiformamido)propanamido)metil)furan-2-carboxamida |
| WO2017006295A1 (en) * | 2015-07-08 | 2017-01-12 | Glaxosmithkline Intellectual Property (No.2) Limited | Hydroxy formamide derivatives and their use |
| EP3319961A1 (en) | 2015-07-09 | 2018-05-16 | Glaxosmithkline Intellectual Property (No. 2) Limited | N-hydroxyformamide compounds and compositions comprising them for use as bmp1, tll1 and/or tll2 inhibitors |
| CN106699604B (zh) * | 2017-01-09 | 2019-01-01 | 四川同晟生物医药有限公司 | 一种沙库比曲及其中间体的制备方法 |
| US9862675B1 (en) * | 2017-07-05 | 2018-01-09 | King Fahd University Of Petroleum And Minerals | Method of N-formylating amines with a phosphonic anhydride |
| IL300088A (en) * | 2020-07-31 | 2023-03-01 | Glaxosmithkline Ip Dev Ltd | Antigen binding protein |
| US20240092807A1 (en) * | 2020-10-07 | 2024-03-21 | VenatoRx Pharmaceuticals, Inc. | Process for boron-containing compounds |
| CN114230463B (zh) * | 2021-12-28 | 2024-06-21 | 青岛科技大学 | 一种邻羟基苯甲酸苯酯的后处理方法 |
| CN114195638B (zh) * | 2021-12-28 | 2023-07-14 | 青岛科技大学 | 一种邻羟基苯甲酸苯酯的制备方法 |
Family Cites Families (60)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US5539082A (en) | 1993-04-26 | 1996-07-23 | Nielsen; Peter E. | Peptide nucleic acids |
| US5641625A (en) | 1992-05-22 | 1997-06-24 | Isis Pharmaceuticals, Inc. | Cleaving double-stranded DNA with peptide nucleic acids |
| US6451968B1 (en) | 1991-05-24 | 2002-09-17 | Isis Pharmaceuticals, Inc. | Peptide nucleic acids |
| US6228982B1 (en) | 1992-05-22 | 2001-05-08 | Benget Norden | Double-stranded peptide nucleic acids |
| GB9311386D0 (en) | 1993-06-02 | 1993-07-21 | Pna Diagnostics As | Nucleic acid analogue assay procedures |
| GB2285445A (en) | 1993-12-06 | 1995-07-12 | Pna Diagnostics As | Protecting nucleic acids and methods of analysis |
| GB2289677A (en) | 1993-12-06 | 1995-11-29 | Pna Diagnostics As | Labelling of nucleic acid analogue-peptide chimerae |
| JP3307945B2 (ja) | 1994-10-06 | 2002-07-29 | アイシス・ファーマシューティカルス・インコーポレーテッド | ペプチド核酸コンジュゲート |
| CN1220608A (zh) | 1996-05-30 | 1999-06-23 | 威斯康星铝研究基金会 | 哺乳动物的特洛德样基因和蛋白质 |
| US6008017A (en) | 1997-01-02 | 1999-12-28 | Smithkline Beecham Corporation | Human cardiac/brain tolloid-like protein |
| US6037139A (en) | 1997-06-03 | 2000-03-14 | Wisconsin Alumni Research Foundation | System for assaying modulators of procollagen maturation |
| DE19726427A1 (de) | 1997-06-23 | 1998-12-24 | Boehringer Mannheim Gmbh | Pyrimidin-2,4,6-trion-Derivate, Verfahren zu deren Herstellung und diese Verbindungen enthaltende Arzneimittel |
| EP0922702A1 (de) | 1997-12-13 | 1999-06-16 | Roche Diagnostics GmbH | Neue Azulenderivate und diese enthaltende Arzneimittel |
| JP2002510487A (ja) | 1998-04-03 | 2002-04-09 | ウイスコンシン アラムニ リサーチ ファンデーション | 哺乳類のｔｏｌｌｏｉｄ様遺伝子及びタンパク質 |
| DE19850072A1 (de) | 1998-10-30 | 2000-05-04 | Bayer Ag | Phosphinat-Peptidanaloga zur Behandlung von fibrotischen Erkrankungen |
| CN1330661A (zh) * | 1998-12-10 | 2002-01-09 | 霍夫曼-拉罗奇有限公司 | 原胶原c端蛋白酶抑制剂 |
| CA2355902A1 (en) | 1998-12-22 | 2000-06-29 | F. Hoffmann-La Roche Ag | Sulfonamide hydroxamates |
| IL148225A0 (en) | 1999-09-01 | 2002-09-12 | Subsidiary No 3 Inc | Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes |
| WO2001016323A2 (en) | 1999-09-01 | 2001-03-08 | Subsidiary N0.3, Inc. | Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes |
| GB9930570D0 (en) | 1999-12-23 | 2000-02-16 | Pfizer Ltd | Therapy |
| DK1272647T3 (en) | 2000-04-11 | 2014-12-15 | Genentech Inc | Multivalent antibodies and uses thereof |
| US7816407B2 (en) | 2000-06-15 | 2010-10-19 | University Of Kentucky Research Foundation | Agmatine and agmatine analogs in the treatment of epilepsy, seizure, and electroconvulsive disorders |
| EP2083005A1 (en) | 2000-09-29 | 2009-07-29 | TopoTarget UK Limited | Carbamic acid compounds comprising an amide linkage as HDAC inhibitors |
| US20050147602A1 (en) | 2000-10-19 | 2005-07-07 | Maine Medical Center Research Institute | Compositions, methods and kits relating to CTHRC1, a novel modulator of collagen matrix |
| US6630325B1 (en) | 2000-10-19 | 2003-10-07 | Maine Medical Center Research Institute | Compositions, methods and kits relating to remodel |
| GB0031321D0 (en) | 2000-12-21 | 2001-02-07 | Pfizer Ltd | Treatment |
| GB0108097D0 (en) | 2001-03-30 | 2001-05-23 | Pfizer Ltd | Compounds |
| GB0108102D0 (en) | 2001-03-30 | 2001-05-23 | Pfizer Ltd | Compounds |
| US6821972B2 (en) | 2001-03-30 | 2004-11-23 | Pfizer Inc. | 3-heterocyclylpropanohydroxamic acid PCP inhibitors |
| WO2003002528A2 (en) | 2001-06-29 | 2003-01-09 | Subsidiary No. 3 | Compositions and methods for inhibiting human immunodeficiency virus infection by down-regulating human cellular genes |
| DE10134243A1 (de) | 2001-07-14 | 2003-03-27 | Burchardt Elmar Reinhold | Phosphimat-Peptidanalyse zur Behandlung von fibrotischen Erkrankungen |
| PT1442024E (pt) | 2001-11-01 | 2008-06-12 | Janssen Pharmaceutica Nv | Derivados aminobenzamida como inibidores da glicogénio sintase quinase 3$g(b) |
| AUPS160602A0 (en) | 2002-04-08 | 2002-05-16 | University Of Queensland, The | Therapeutic method |
| CA2490989A1 (en) | 2002-05-13 | 2003-11-20 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment of graft failure |
| BR0314270A (pt) | 2002-09-16 | 2005-08-02 | Univ Johns Hopkins | Ativação de miostatina com metaloprotease e processos de modulação da atividade da miostatina |
| WO2004052919A2 (en) | 2002-12-11 | 2004-06-24 | Smithkline Beecham Corporation | Peptide deformylase inhibitors |
| WO2004108130A1 (en) | 2003-06-03 | 2004-12-16 | Beth Israel Deaconess Medical Center | Methods and compounds for the treatment of vascular stenosis |
| US7332485B2 (en) | 2003-07-08 | 2008-02-19 | Smithkline Beecham Corp | Peptide deformylase inhibitors |
| WO2005065396A2 (en) | 2003-12-31 | 2005-07-21 | Osteotech, Inc. | Improved bone matrix compositions and methods |
| WO2006057951A2 (en) | 2004-11-22 | 2006-06-01 | Beth Israel Deaconess Medical Center | Methods and compositions for the treatment of graft failure |
| BRPI0516383A (pt) * | 2004-12-21 | 2008-09-02 | Serono Lab | derivados cìclicos de sulfonil amino e o uso dos mesmos |
| US20090305963A1 (en) | 2005-01-19 | 2009-12-10 | Sukhatme Vikas P | Lipocalin 2 for the Treatment, Prevention, and Management of Cancer Metastasis, Angiogenesis, and Fibrosis |
| WO2007006858A2 (en) | 2005-07-12 | 2007-01-18 | Oy Jurilab Ltd | Method for treatment of cardiovascular and metabolic diseases and detecting the risk of the same |
| US20070041905A1 (en) | 2005-08-19 | 2007-02-22 | Hoffman Rebecca S | Method of treating depression using a TNF-alpha antibody |
| TWI323734B (en) | 2005-08-19 | 2010-04-21 | Abbott Lab | Dual variable domain immunoglobulin and uses thereof |
| US7612181B2 (en) | 2005-08-19 | 2009-11-03 | Abbott Laboratories | Dual variable domain immunoglobulin and uses thereof |
| JP5199109B2 (ja) * | 2005-11-24 | 2013-05-15 | メルク セローノ ソシエテ アノニム | Ｎ−ヒドロキシアミド誘導体およびその使用 |
| CA2658582C (en) | 2006-07-21 | 2013-12-10 | Genera Doo | Bmp-1 procollagen c-proteinase for diagnosis and treatment of bone and soft tissue defects and disorders |
| WO2008024767A2 (en) | 2006-08-21 | 2008-02-28 | Wisconsin Alumni Research Foundation | Method and composition for treating a fibrotic disorder |
| EP1932907A1 (en) | 2006-12-12 | 2008-06-18 | Novartis AG | Crystal structure of the catalytic domain of tolloid-like protease 1 and uses thereof |
| US20090076062A1 (en) | 2007-09-13 | 2009-03-19 | Juergen Klaus Maibaum | Organic Compounds |
| UA108596C2 (xx) | 2007-11-09 | 2015-05-25 | Інгібітори пептиддеформілази | |
| WO2009097893A1 (en) | 2008-02-04 | 2009-08-13 | Proyecto De Biomedicina Cima, S.L. | Methods for the treatment of cardiac disease associated to myocardial fibrosis using an inhibitor of pcp |
| CN108165548B (zh) | 2008-09-22 | 2022-10-14 | 菲奥医药公司 | 减小大小的自递送RNAi化合物 |
| US20110293526A1 (en) | 2008-11-20 | 2011-12-01 | University Of Southern California | Compositions and methods to modulate hair growth |
| US8895497B2 (en) | 2009-12-04 | 2014-11-25 | Dcb-Usa, Llc | Cathepsin S inhibitors |
| JP6133402B2 (ja) | 2012-04-25 | 2017-05-24 | ゲネラ・イストラジヴァンジャ・ディーオーオー | 急性心筋梗塞を処置および診断するための方法および組成物 |
| PE20160998A1 (es) * | 2014-01-10 | 2016-10-26 | Glaxosmithkline Intellectual Property (No 2) Ltd | Derivados de n-((3-(n-hidroxiformamido)propanamido)metil)furan-2-carboxamida |
| WO2017006295A1 (en) | 2015-07-08 | 2017-01-12 | Glaxosmithkline Intellectual Property (No.2) Limited | Hydroxy formamide derivatives and their use |
| EP3319961A1 (en) | 2015-07-09 | 2018-05-16 | Glaxosmithkline Intellectual Property (No. 2) Limited | N-hydroxyformamide compounds and compositions comprising them for use as bmp1, tll1 and/or tll2 inhibitors |
-
2015
- 2015-01-09 PE PE2016001113A patent/PE20160998A1/es unknown
- 2015-01-09 CN CN201580013152.8A patent/CN106103431B/zh not_active Expired - Fee Related
- 2015-01-09 AU AU2015205370A patent/AU2015205370B2/en not_active Ceased
- 2015-01-09 US US15/110,776 patent/US10450288B2/en not_active Expired - Fee Related
- 2015-01-09 CR CR20160316A patent/CR20160316A/es unknown
- 2015-01-09 WO PCT/IB2015/050179 patent/WO2015104684A1/en not_active Ceased
- 2015-01-09 CA CA2936467A patent/CA2936467A1/en not_active Abandoned
- 2015-01-09 BR BR112016016130A patent/BR112016016130A2/pt not_active Application Discontinuation
- 2015-01-09 SG SG11201605539SA patent/SG11201605539SA/en unknown
- 2015-01-09 TW TW104100718A patent/TW201620887A/zh unknown
- 2015-01-09 KR KR1020167021496A patent/KR20160106684A/ko not_active Withdrawn
- 2015-01-09 CN CN201910119933.5A patent/CN109970797A/zh active Pending
- 2015-01-09 JP JP2016545920A patent/JP2017507915A/ja not_active Ceased
- 2015-01-09 EA EA201691412A patent/EA031654B1/ru not_active IP Right Cessation
- 2015-01-09 MA MA39171A patent/MA39171A1/fr unknown
- 2015-01-09 EP EP15702008.2A patent/EP3092233A1/en not_active Withdrawn
- 2015-01-09 MX MX2016009064A patent/MX2016009064A/es unknown
- 2015-01-09 UA UAA201608690A patent/UA118278C2/uk unknown
-
2016
- 2016-07-07 IL IL246653A patent/IL246653A0/en unknown
- 2016-07-07 PH PH12016501349A patent/PH12016501349A1/en unknown
- 2016-07-07 CL CL2016001746A patent/CL2016001746A1/es unknown
- 2016-07-08 DO DO2016000170A patent/DOP2016000170A/es unknown
-
2019
- 2019-09-03 JP JP2019160658A patent/JP2020011968A/ja active Pending
- 2019-10-17 US US16/655,784 patent/US20200095217A1/en not_active Abandoned
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2017507915A5 (OSRAM) | ||
| JP2008505874A5 (OSRAM) | ||
| JP2008530101A5 (OSRAM) | ||
| JP2009528296A5 (OSRAM) | ||
| JP2012526728A5 (OSRAM) | ||
| CA2435067A1 (en) | Malonyl-coa decarboxylase inhibitors useful as metabolic modulators | |
| JP2016530310A5 (OSRAM) | ||
| JP2005522438A5 (OSRAM) | ||
| AU2016333963B2 (en) | PPAR agonists, compounds, pharmaceutical compositions, and methods of use thereof | |
| JP2016534134A5 (OSRAM) | ||
| JP2013518050A5 (OSRAM) | ||
| CN109071459B (zh) | Ppar激动剂、化合物、药物组合物以及它们的使用方法 | |
| JP2019531320A5 (OSRAM) | ||
| JP2010518067A (ja) | 抗寄生虫剤 | |
| RU2012122615A (ru) | Новые соединения в качестве модуляторов рецепторов с терапевтическим действием | |
| RU2007119427A (ru) | Соединения, являющиеся ингибиторами гликогенфосфорилазы, и фармацевтические композиции на их основе | |
| JP2004502670A5 (OSRAM) | ||
| JP2007308471A5 (OSRAM) | ||
| JP2005506308A5 (OSRAM) | ||
| JP2014508106A (ja) | スフィンゴシン−１−リン酸−１受容体モジュレーターとしてのアルキンおよびアルケン誘導体 | |
| JP2013517322A5 (OSRAM) | ||
| JPWO2023195529A5 (OSRAM) | ||
| RU2012119249A (ru) | Соединения кумарина в качестве модуляторов рецепторов для терапевтического использования | |
| JP2010500978A5 (OSRAM) | ||
| RU2013128328A (ru) | Новые фосфоновые кислоты как модуляторы рецептора s1p |